Multidrug-resistant tuberculosis: Rapid molecular detection with MTBDRplus® assay in clinical samples;Tuberculose multirresistente: Detecção directa em amostras respiratórias com o método de genética molecular MTBDRplus®

Revista Portuguesa de Pneumologia

Volumn 15, Issue 3, 2009, Pages 353-365

  Macedo, Rita ^a   Amorim, António ^a   Pereira, Edna ^a  

^a Public Health Laboratory Mycobacteriology Tuberculosis   (Portugal)

Author keywords

Laboratory diagnosis; Multi drug resistance; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; BACTERIAL DNA;

ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY ANALYSIS; SPUTUM ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; GENETICS; SENSITIVITY AND SPECIFICITY; TIME;

DNA, BACTERIAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 68949212200     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0873-2159(15)30140-9     Document Type: Article

References (23)

1. World Health Organization. 2006. Guidelines for the programmatic management of drug resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: World Health Organization.
2. SVIG -TB, Direcção -Geral da Saúde. Ponto da situação epidemiológica e de desempenho em 2007, dados preliminares. 2007.
3. World Health Organization. Antituberculous drug resistance in the World, Report number 3, 2005.
4. Aziz MA, Wright A, Laszlo A, de Muuynck A, Portaels F, van Deun A, Wells C, Nunn P, Blanc L, Raviglione M. Epidemiology of antituberculosis drug resistance (the Global Project on Anti -tuberculosis Drug Resistance Surveillance) an updated analysis. Lancet 2006; 368: 2142 -2154.
5. Kochi A, Vareldzis B, Styblo K. 1993. Multidrug--resistant tuberculosis and its control. Res Microbiol 1993; 144: 104 -110.
6. Raviglione MC, Smith MB. XDR Tuberculosis - Implications for global public health. N Engl J Med 2007; 356: 656 -659.
7. World Health Organization. Addressing the threat of tuberculosis caused by extensively drug resistant Mycobacterium tuberculosis (XDR -TB). Weekly Epidemiological Record 2006; 81: 385 -396.
8. Parsons LM, Somoskövi A, Urbanczik R, Salfinger M. Laboratory diagnostic aspects of drug resistant tuberculosis. Front Biosci 2004; 9: 2086 -2105.
9. Coll P. Fármacos con actividad frente a Mycobacterium tuberculosis. Enferm Infecc Microbiol Clin 2003; 21: 299 -308.
10. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001; 2: 164 -168.
11. Shoeb HA, Bowman Jr BU, Ottolenghi AC, Merola AJ. Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1985; 27: 404-407.
12. Pym AS, Saint -Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70: 4955 -4960.
13. Li Z, Kelley C, Collins F, Rouse D, Morris S. Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 1998; 177: 1030 -1035.
14. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs Jr WR. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994: 263: 227 -230.
15. Macedo R, Perdigão J, Portugal I, Brum L. MDR--TB in Lisbon area: data report from 2004 to 2006. 28th Annual Congress of European Society of Mycobacteriology (Abstract book), 2007:37.
16. Mäkinen J, Marttila HJ, Marjamäki M, Viljanen MK, Soini H. Comparison of two commercially available DNA line probe assays for detection of multidrug--resistant Mycobacterium tuberculosis. J Clin Microbiol 2006; 44:350 -352.
17. Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 2006; 44: 20 -28.
18. Bang D, Bengård Andersen A, Thomsen VØ. Rapid genotypic detection of rifampin- and isoniazid -resistant Mycobacterium tuberculosis directly in clinical specimens. J Clin Microbiol, 2006; 44:2605 -2608.
19. Cavusoglu C, Turhan A, Akinci P, Soyler I. Evaluation of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol 2006; 44:2338 -2342.
20. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol, 2005; 43:3699 -3703.
21. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM. Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J Clin Microbiol, 2006; 44: 2485 -2491.
22. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M. Use of smear -positive samples to assess the PCR -based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol 2006; 44:4459 -4463.
23. Hillemann D, Rüsch -Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45:2635 -2640.